Risk of arterial (ATE) and venous thromboembolism (VTE) in a population-based cohort of bevacizumab-treated metastatic colorectal cancer (mCRC) patients.
Irene S. Yu
No relevant relationships to disclose
Winson Y. Cheung
No relevant relationships to disclose